AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02169960 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: This Way Up
Description: Cognitive Behavioral Therapy online intervention for Depression and Anxiety
Study NCT02169960 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resiliency Training
Description: Op Volle Kracht (OVK)
Study NCT02668692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 80185 gel
Description: calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
Study NCT02668692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dovobet ® ointment
Description: calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
Study NCT04171063 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Thoracic compressor
Description: The intervention is the use of the thoracic compressor for the conservative treatment of pectus carinatum
Study NCT00534924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit C
Study NCT00534924 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postconditioning
Study NCT00534924 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no intervention
Study NCT00748332 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortimel Extra®
Description: 2 bottles (600 kcal, 40 g proteins) per day
Study NCT00748332 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortimel Care®
Description: Fortimel Care® : 2 bottles (660 kcal, 36 g proteins, 2.38 g EPA) per day
Study NCT01500265 — intervention group
Intervention type: BIOLOGICAL
Intervention: plasma and urine samples, sample with ADN
Description: plasma and urine samples every three months Sample with ADN at baseline
Study NCT04299256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benson relaxation combined with music therapy
Description: In the first interview, the patient information delivered a training booklet explaining the definition, purpose, benefits and application techniques of BRT and music therapy to the patients in the intervention group. After patients reviewed the details in the training booklet, a weekly schedule was planned for each patient based on their hemodialysis days. For the initiation of the intervention, patients were invited to the hemodialysis unit at the hospital 45 min prior to their hemodialysis sessions. All the participants wore black eye patches to provide a dim environment and to focus better on their breath and the music piece. Then, the patients information opened the music piece and gave Benson Relaxation Technique comments in a slightly lower voice. Each session lasted for 20 min, and the music piece was switched off as Benson Relaxation Technique ended. The music piece used in the study was Daniel Kobelco's non-verbal classical song.
Study NCT03286881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief individual psychotherapy
Description: Individual brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in secondary care.
Study NCT03286881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief group psychotherapy
Description: Group brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in primary care.
Study NCT03286881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined intervention
Description: Traditional psychotherapy and medication provided by a clinical psychologist and a psychiatrist in secondary care.
Study NCT03286881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimum psychological intervention
Description: Psychoeducation and bibliotherapy provided by a trained general practitioner in primary care.
Study NCT03286881 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual treatment
Description: Medication provided by a general practitioner.
Study NCT02092168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Study NCT02421146 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.
Study NCT02421146 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation - Sham
Description: Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.
Study NCT04038385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multilevel Behavioral Intervention
Description: Behaviorally-focused intervention grounded in the Social Ecological Model and Social Cognitive Theory to promote vegetable intake and the redemption of seasonal Farmers' Market Nutrition Program vouchers and monthly Cash Value Vouchers at farmers' markets.
Study NCT00633893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Tablets, Oral, twice daily, 12 months
Study NCT00633893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, twice daily, 12 months
Study NCT02891772 — intervention group
Intervention type: PROCEDURE
Intervention: ultrasonographic measurement of corrected flow time(FTc) in carotid artery
Description: Corrected carotid artery flow time is measured using 10-5 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time). The blood pressure was taken before anesthetic induction and every two minutes after anesthetic induction till ten minutes after endotracheal intubation.
Study NCT02831283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-PBR28
Description: 11C-PBR28 is a PET radioligand that binds to the 18 kDa translocator protein (TSPO), a marker of inflammation. 11C-PBR28 has previously been administered in humans. 11C-PBR28 will be administered at activity of up to 20 mCi per injection.
Study NCT02831283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 11C-PBR28
Description: 11C-PBR28 is a PET radioligand that binds to the 18 kDa translocator protein (TSPO), a marker of inflammation. 11C-PBR28 has previously been administered in humans. 11C-PBR28 will be administered at activity of up to 20 mCi per injection.
Study NCT02831283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Florbetaben
Description: 18F-Florbetaben (Neuraceq) has FDA approval for human use in evaluation of Alzheimer's disease. 18F-Florbetaben will be administered at activity up to 8.1 mCi per injection.
Study NCT02831283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-Florbetaben
Description: 18F-Florbetaben (Neuraceq) has FDA approval for human use in evaluation of Alzheimer's disease. 18F-Florbetaben will be administered at activity up to 8.1 mCi per injection.
Study NCT02831283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar puncture (optional)
Description: Subjects have the option to have lumbar puncture performed for the measurement of inflammatory markers in cerebrospinal fluid.
Study NCT02831283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar puncture (optional)
Description: Subjects have the option to have lumbar puncture performed for the measurement of inflammatory markers in cerebrospinal fluid.
Study NCT01037751 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: 1-on-1 interview with study doctor or staff member, during regularly scheduled, standard of care clinic visit taking 30 minutes.
Study NCT01037751 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey
Description: Complete 3 Questionnaires during clinic visit, about 10 minutes to complete all.
Study NCT05469100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally
Study NCT00092222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: 1.3 mg/m2 IV days 1, 4, 8, and 11. Cycle length is 21 days.
Study NCT00092222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: Cycle 1: Valganciclovir 900 mg PO BID x 7-21 days in outpatient setting; 900 mg PO q 12 hours x 7-21 days for inpatients; Cycle 2 and beyond: 900 mg PO BID x 7 days for outpatients; 900 mg PO q 12 hours x 7 days (Intravenous ganciclovir 5 mg/kg may be substituted) for inpatients
Study NCT00092222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 10 mg/m2 /day CIVI over 24 hours x 4 days (days 1-4) of 21 day cycle.
Study NCT00092222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 0.4 mg/m2 /day CIVI over 24 hours x 4 days (days 1-4) of 21 day cycle.
Study NCT00092222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide: if CD4 \< 100 cells/mm3, 187 mg/m2 IV (Day 5) if CD4 greater than or equal to 100 cells/mm3, 375 mg/m2 IV (Day 5) of 21 day cycle.
Study NCT00092222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim (G-CSF)
Description: Filgrastim 300 micrograms subcutaneous daily beginning day 6 until absolute neutrophil count recovery 5000 cells/mm3 (Pegfilgrastim may be substituted with PI approval, at the recommended dose of one 6mg syringe)
Study NCT00092222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 60 mg/m2/day PO x 5 days (days 1-5)of 21 day cycle.
Study NCT00092222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Maximum daily dose of 40 mg given as a single agent on 21 day cycle.
Study NCT00092222 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation Only
Description: Observation of symptoms
Study NCT00871676 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: 16 weekly followed by 8 monthly group behavioral weight loss sessions.
Study NCT02779855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Description: Talimogene laherparepvec injection. Phase I: Dose escalation. Phase II: Treatment at Maximum Tolerated Dose (MTD) from Phase I. The MTD dose level is defined as the highest dose level with ≤1 out of 6 patients experiencing a dose limiting toxicity (DLT).
Study NCT02779855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel chemotherapy infusion. The paclitaxel weekly dose is fixed at 80 mg/m\^2.
Study NCT00871676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification plus gum
Description: 16 weekly followed by 8 monthly group behavioral weight loss sessions. Subjects were also given gum along with instructions for times and occasions to chew with the aim of facilitating weight loss and appetite control.
Study NCT01488188 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Administration of 1 dose (0.2 ml) by nasal route
Study NCT01488188 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Administration of 1 dose (0.2 ml) by sublingual route
Study NCT00959699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PegIFN-2b
Description: PegIFN-2b (1.5 μg/kg/week subcutaneously)
Study NCT00959699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIFN-2b
Description: PegIFN-2b (1.5 μg/kg/week subcutaneously)
Study NCT00959699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RBV
Description: Ribavirin (600-1400 mg/day, orally, divided into two daily doses)
Study NCT00959699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBV
Description: Ribavirin (600-1400 mg/day, orally, divided into two daily doses)
Study NCT05070741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heat Therapy
Description: Subjects will undergo 12 hot water immersions of 40.5 degrees Celsius for approximately 45 minutes per session over 4 weeks. Subjects will be immersed up to the shoulder in a 40°C hot tub until rectal temperature (Tre) increases by 1°C (\~20 minutes). Subjects will then remain in the water bath submerged to waist level to maintain Tre between 38.5 and 39.0°C for another 30 minutes (approx. total time submerged \~50 minutes). Following hot water immersion, subjects will be monitored for another 10 min, or until Tre falls below 38.5°C. Core temperature will be monitored using either 1) a rectal probe with sterile disposable sheaths or 2) a sterile disposable rectal thermistor probe (401 A/C, Advanced Industrial Systems, Inc., Harrods Creek, KY) to be inserted \~1 inch past the anal sphincter (inserted by participant). Heart rate and blood pressure will be monitored throughout the treatment. Subjects will be continually monitored and removed from the hot bath if Tre exceeds 39.5°C.
Study NCT00959699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Boceprevir
Description: Placebo to boceprevir (orally, three times per day)
Study NCT00959699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boceprevir
Description: Boceprevir (800 mg, orally, three times per day)
Study NCT04159701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3454738
Description: Administered IV
Study NCT04159701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT02622048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Triple P Positive Parenting Programme
Description: 10 week self-directed (guided) parenting intervention promoting self-belief, parenting confidence/self-efficacy and problem solving skills.
Study NCT04313673 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: second trimester ultrasonography
Description: Patients undergoing routine antenatal screening between 18-24 weeks and measuring cervical length with transabdominal ultrasonography in the same session
Study NCT01553591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eluxadoline
Description: Oral tablets twice daily
Study NCT01553591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets twice daily
Study NCT00260091 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrauterine insemination
Description: An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
Study NCT00260091 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infertility
Description: This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
Study NCT03151538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training Mixed With Play
Description: To assess effects of training program which includes mixed exercises with playing.Study included 90 pre-school children who suffer from pes planus and increased femoral anteversion angle. Demographic data, navicular height, weight-bearing and non-weight bearing of subtalar joint motion, metatarsal width(weight and non-weight), range of hallux valgus,height of foot, tension of Achilles tendon, habits of W standing(hour/day), angle of Quadriceps(Q degree), angle of hip rotation were recorded . Craig Test, foot posture index, Chippaux-Smirak Index(CSI),Beighton hypermobility score, valgus index, thigh foot angle examination were used. CSI measurements were positive correlation with severity of pes planus.
Study NCT03151538 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Controlled
Description: First and last measurements will be done. There will be no intervention. Study will include 30 healthy pre-school children. Demographic data, navicular height, weight-bearing and non-weight bearing of subtalar joint motion, metatarsal width(weight and non-weight), range of hallux valgus,height of foot, tension of Achilles tendon, habits of W standing(hour/day), angle of Quadriceps(Q degree), angle of hip rotation were recorded . Craig Test, foot posture index, Chippaux-Smirak index(CSI),Beighton hypermobility score, valgus index, thigh foot angle examination were used.
Study NCT02120469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO
Study NCT02120469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Given IV
Study NCT02120469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02120469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT04500223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Cranioflexion exercise plus cardiopulmonary exercise
Description: Intervention:Cervical Cranioflexion exercise plus cardiopulmonary exercise
Study NCT04500223 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical stretch exercise plus cardiopulmonary rehabilitation
Description: control:Cervical stretch exercise plus cardiopulmonary rehabilitation
Study NCT02971007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Encochleated Amphotericin B (CAMB)
Description: lipid-crystal nano-particle formulation amphotericin B
Study NCT02971007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Study NCT01704976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SR-WBV
Description: Participants will undergo a training program set over four weeks, three times a week with 3 to 6 Hz, Noise 4.
Study NCT01704976 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SR-WBV
Description: Participants will undergo a training program set over four weeks three times a week with 1 Hz, Noise 1.
Study NCT02620046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab SC
Description: Vedolizumab SC 108 mg injection
Study NCT01554189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8325
Description: MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)
Study NCT01554189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match MK-8325 capsules, orally, once per day for 5 days
Study NCT01547962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gintuit
Description: Gintuit is prepared in a S fold and trimmed to fit the prepared wound bed, with a standardized width of 5 mm and sutured in place with a 5/0 gut suture.
Study NCT01547962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: autologous Free Gingival Graft (FGG)
Description: Autologous FGG harvested from the subject's palate, the width of the FGG will be 5 mm and sutured in place with a 5/0 gut suture.
Study NCT02741310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by intravenous infusion
Study NCT02741310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intravenous infusion
Study NCT02741310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: Administered by two 6 mg subcutaneous injections 1 hour apart on day 2 and day 5
Study NCT02741310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sumatriptan
Description: Administered by two 6 mg subcutaneous injections 1 hour apart on day 2 and day 5
Study NCT02741310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered by intravenous infusion
Study NCT02977507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lytera 2.0
Description: Lytera 2.0 applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.
Study NCT02977507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% Hydroquinone Topical Cream
Description: 4% Hydroquinone Topical Cream applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.
Study NCT02977507 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SkinMedica Facial Cleanser
Description: SkinMedica facial cleanser applied to the face as directed.